PhytoMedical's BDC-O3 compound shown to elevate HDL

By Elaine Rigoli

Tampa, Fla., May 16 - PhytoMedical Technologies, Inc. announced that research and development of its proprietary BDC-03 compound has been expanded to include investigations of high density lipoproteins (HDL), shown in a study to be favorably elevated by BDC-03.

Raised levels of HDL - often referred to as "good cholesterol" - are important in preventing the dangerous build-up of wax-like, fatty plaque in the inner lining of the artery of the heart.

Also, the results of an initial animal study showed that BDC-03 has pharmacologically active elements that have the potential to reduce body fat percentage, lower cholesterol and increase lean muscle, the company said in a news release.

The prospective capacity of BDC-03 to induce overall weight gain in the form of lean muscle mass has focused PhytoMedical's attention to the development of a new compound for the treatment of cachexia, a condition that afflicts 25% of all AIDS patients and upwards of 90% of all advanced cancer patients, the release said.

The company said half of all cancer-related deaths are a result of cachexia, not the cancer itself.

Located in Princeton, N.J., PhytoMedical is a biopharmaceutical company focused on the development of plant-derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity and diabetes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.